Merck & Co., Inc. (NYSE:MRK) is among the 11 Dogs of the Dow Dividend Stocks to Buy Now, known for its reliability in the lineup.

Facing stock pressure from Keytruda reliance, Merck (MRK) diversified by acquiring UK biotech Verona Pharma for $10 billion, adding COPD treatment Ohtuvayre to its portfolio.

In its first quarter earnings, Merck (MRK) highlighted strong progress driven by commercialized medicines and ongoing pipeline advancements. The company is focused on capitalizing on opportunities and advancing innovations for long-term value.

Merck & Co., Inc. (NYSE:MRK) has a dividend growth history spanning 16 years, currently offering a quarterly dividend of $0.81 per share with a 3.82% yield as of July 26.

While Merck (MRK) is recognized for investment potential, some analysts believe certain AI stocks offer greater upside and less downside risk, particularly in the AI sector.

Read more at Yahoo Finance: Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup